IP31: Prostate Cancer: Localized: Active Surveillance
Saturday, May 16, 2026 9:30 AM to 11:30 AM · 2 hr. (America/New_York)
145AB
Poster and Podium Sessions
Oncology: Prostate
Saturday, May 16
IP31-01: Introducing PSMA Density: A Quantitative PET Biomarker for Predicting Pathologic Upgrading in Men on Active Surveillance
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Neeraja Tillu
IP31-02: Non-Invasive Urine Test Predicts the Need for Biopsy in Patients on Active Surveillance for Prostate Cancer: Prospective Multisite Validation and Comparison with MRI
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Cameron Britton · Vanderbilt University Medical Center
IP31-03: Adherence to the Mediterranean and plant-based diets is associated with reduced risk of prostate cancer grade progression on active surveillance
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Zhuo Su · Johns Hopkins
IP31-04: 25+ Years of Active Surveillance for Prostate Cancer: Is There an Increased Burden of Treatment in Those Who Progress?
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Noa Ferziger · Albert Einstein College of Medicine
IP31-05: Reclassification to grade group 3 or above on active surveillance is associated with adverse clinical outcomes
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Rilwan Babajide
IP31-06: The Nature of Progression on Active Surveillance for Grade Group 2 Prostate Cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Kevin Shee · UCSF Urology
IP31-07: Active surveillance in ISUP grade 2 prostate cancer: a retrospective analysis of discontinuation rates and predictive factors
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
LARA RODRIGUEZ SANCHEZ · Institut Médico-chirurgical Montsouris
IP31-08: Re-evaluating Active Surveillance Eligibility in Prostate Cancer Based on Gleason Pattern 4 Quantification
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Sean Fletcher · Johns Hopkins
IP31-09: Personalized, risk-adapted prostate cancer active surveillance in the era of molecular resonance imaging: Results from a large, prospective cohort with focus on systematic and targeted biopsy outcomes
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Zhuo Su · Johns Hopkins
IP31-10: Factors associated with extreme grade reclassification for prostate cancer patients on active surveillance in the modern era
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Joseph Nicolas · McGaw Medical Center of Northwestern University
IP31-11: Trends in the Use of Active Surveillance for Management of Low-Risk Prostate Cancer within a Large National Health System
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Grace Lee
IP31-12: Can active surveillance be safely expanded to intermediate-risk disease?
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
MASAHIRO TOIDE · Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
IP31-14: Diagnostic Genomic Classifiers Are Predictive of Upgrading But Do Not Obviate Confirmatory Biopsy in Active Surveillance
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
James Nie
IP31-15: A Phase 1 Safety, PK and Preliminary Efficacy Study of Localized Therapy using Enolen® (Enzalutamide) Implants for Early-Stage Prostate Cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Braden Millan · National Cancer Institute
IP31-16: Bladder Outlet Procedures Reduce Definitive Therapy in Men on Active Surveillance for Prostate Cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Ernie Morton
IP31-17: Active Surveillance after Incidental Prostate Cancer at Time of HoLEP: How Often Does Confirmatory Biopsy Reclassify Grade Group?
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Nabila Khondakar · SUNY Downstate / National Institutes of Health
IP31-18: Prognostic value of MRI for time to grade progression in men on active surveillance for prostate cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Seyed Hossein Hosseini Sharifi · University of Miami
IP31-19: Contemporary rates and practice-level variation in disease burden assessment amongst prostate cancer active surveillance patients: data from a statewide quality collaborative
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Patrick Lewicki · University of Michigan
IP31-20: Association of Biopsy-Based Genomic Classifier and Initial Treatment for Prostate Cancer: Results from a National Clinical–Genomic Linkage
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Michael Leapman · Yale University Department of Urology
IP31-21: A Risk-Based Model to Identify Active Surveillance Patients Requiring Confirmatory Biopsy: A Contemporary MRI-Based Cohort Study
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Leonardo Quarta
IP31-22: Clinical utility and prognostic value of a six-gene signature for aggressive prostate cancer among clinically low risk patients
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Debra Higgins · OncoAssure Ltd
IP31-23: An AI-Based Decision Support Model for Personalized Management of Patients on Active Surveillance
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Dimple Chakravarty · Icahn School of Medicine At Mount Sinai
IP31-24: Predictors of Progression During Active Surveillance for Grade Group 1 Prostate Cancer in the mpMRI Era: Implications for Follow-up Strategies
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Riccardo Leni · IRCCS Ospedale San Raffaele
IP31-25: Contemporary Evaluation of Racial Disparities in Active Surveillance Utilization for Men in the United States
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
John Ashley Pallera
IP31-26: Rate of confirmatory biopsy for prostate cancer patients selected for active surveillance with MRI at diagnosis
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Vivian Wan
IP31-27: Use of the Prostate Health Index in Predicting Adverse Oncologic Outcomes on Active Surveillance for Favorable-Risk Prostate Cancers
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Lisa Newcomb · Fred Hutchinson Cancer Research Center
IP31-28: The Diagnostic Benefit of Perilesional Sampling at the Time of Confirmatory Biopsy in Patients Managed with Active Surveillance for ISUP-GG 1 Prostate Cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Leonardo Quarta
IP31-29: Clinically Insignificant Prostate Cancers Should Not Be Treated As Benign Disease: Risks, Progression and Implications In A Robot-Assisted MRI-Fusion Biopsy Prospective Cohort.
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Nigel Sim · National University of Singapore, Yong Loo Lin School of Medicine
IP31-30: PI-RADS Lesion Diameter on MRI Predicts Upgrading in Active Surveillance
Saturday, May 16, 2026 9:30 AM to 11:30 AM
145AB
Vanessa Natalia Sutristio
